Director/PDMR Shareholding
4basebio PLC announced that on February 10, 2026, Non-executive Directors Dr. Heikki Lanckriet and Mr. Hansjörg Plaggemars acquired 3,000 ordinary shares at 575.82 pence each and 1,000 ordinary shares at 585.00 pence each, respectively. Following these purchases, Dr. Lanckriet's shareholding increased to 1,122,688 shares, representing 7.23% of the issued share capital, while Mr. Plaggemars' aggregate holding with associated persons is 7,667 shares, or 0.05% of the issued share capital. The total issued share capital of the company is 15,538,518 ordinary shares.
Select text to share a quote on X · sign in to keep highlights & notes in your 4BB notes
(AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that on 10 February 2026 it was informed that certain Non-executive Directors of the Company made the following purchases in ordinary shares in the capital of the Company through the market.
Further details are set out in the Notification of Dealing Form below.
| Director / PCA | Number of Ordinary Shares Acquired | Purchase Price (Aggregated) (p) | Shareholding Following Acquisition | Shareholding Following Acquisition as a Percentage of Issued Share Capital |
|---|---|---|---|---|
| Dr. Heikki Lanckriet | 3,000 | 575.82 | 1,122,688 | 7.23% |
| Mr Hansjörg Plaggemars* | 1,000 | 585.00 | 7,667† | 0.05%† |
* Purchase was made by Mr Plaggemars, on behalf of his wife. † Aggregate shareholding of Mr Plaggemars and persons closely associated with him.
The 3,000 and 1,000 additional shares purchased represent approximately 0.02 per cent. and 0.01 per cent. of the Company's issued share capital, respectively.
The issued share capital of the Company comprises 15,538,518 ordinary shares.
| a) | Name | 1) Dr. Heikki Lanckriet 2) Mr Hansjörg Plaggemars |
| 2 | Reason for the notification | |
| a) | Position/Status | 1) Non-executive Director 2) Non-executive Director |
| b) | Initial notification/ Amendment | Initial notification |
| a) | Name | 4basebio plc |
| b) | LEI | 213800E2DX9EAIUNCB30 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares ISIN: GB00BMCLYF79 |
| b) | Nature of the transaction | Acquisition of ordinary shares |
| c) | Price(s) and volume(s) | Price(s) Volume(s) 1) 575.82p 3,000 2) 585.00p 1,000 |
| d) | Aggregated information - Aggregated volume - Aggregated Price | 1) 3,000 2) 1,000 1) 575.82p 2) 585.00p |
| e) | Date of transaction | 10 February 2026 |
| f) | Place of transaction | London Stock Exchange |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.